Prem S. Shah - 30 Mar 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Co-President of Retail
Signature
/s/ Prem S. Shah
Issuer symbol
CVS
Transactions as of
30 Mar 2022
Net transactions value
-$13,044
Form type
4
Filing time
31 Mar 2022, 16:49:58 UTC
Previous filing
18 Mar 2022
Next filing
05 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Options Exercise $546,682 +5,346 +9.1% $102.26 64,417 30 Mar 2022 Direct F1
transaction CVS Common Stock Sale $559,726 -5,346 -8.3% $104.70 59,071 30 Mar 2022 Direct
holding CVS Common Stock (pep) 4,413 30 Mar 2022 Direct F2
holding CVS Common Stock (restricted) 1,925 30 Mar 2022 Direct F3
holding CVS Common Stock (restricted) 6,393 30 Mar 2022 Direct F4
holding CVS Common Stock (restricted) 1,808 30 Mar 2022 Direct F5
holding CVS Common Stock (restricted) 15,427 30 Mar 2022 Direct F6
holding CVS Common Stock (restricted) 2,884 30 Mar 2022 Direct F7
holding CVS ESOP Common Stock 4,539 30 Mar 2022 Direct
holding CVS Common Stock (restricted) 1,866 30 Mar 2022 Direct F8
holding CVS Stock Unit (deferred) 5,672 30 Mar 2022 Direct F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVS Stock Option Options Exercise $0 -5,346 -100% $0.000000* 0 30 Mar 2022 Common Stock 5,346 $102.26 Direct F1, F10
holding CVS Stock Option 2,935 30 Mar 2022 Common Stock 2,935 $104.82 Direct F11
holding CVS Stock Option 1,691 30 Mar 2022 Common Stock 1,691 $62.20 Direct F12
holding CVS Stock Option 12,626 30 Mar 2022 Common Stock 12,626 $54.19 Direct F13
holding CVS Stock Option 34,315 30 Mar 2022 Common Stock 34,315 $58.34 Direct F14
holding CVS Stock Option 32,826 30 Mar 2022 Common Stock 32,826 $74.30 Direct F15
holding CVS Stock Option 26,580 30 Mar 2022 Common Stock 26,580 $75.24 Direct F16
holding CVS Phantom Stock Credits 11,259 30 Mar 2022 Common Stock 11,259 $1.00 Direct F17, F18
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All sales were effected pursuant to a Rule 10b5-1 plan.
F2 Consists of Matching RSUs awarded pursuant to Issuer's Partnership Equity Program, a sub-plan under its ICP, and dividend equivalents on the Matching RSUs. Restrictions lapse on the RSUs on 08/31/2023.
F3 Consists of remaining RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 ICP. Restrictions lapse in two equal installments commencing on 02/28/2022.
F4 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in four equal installments commencing on 04/01/2022.
F5 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions lapse on 04/01/2022.
F6 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in three equal installments commencing on 04/01/2022.
F7 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in two equal installments commencing on 04/01/2022.
F8 Consists of RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan under its 2017 ICP. Restrictions lapse in three equal installments commencing on 02/26/2022.
F9 Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
F10 Option becomes exercisable in four equal installments commencing 04/01/2016.
F11 Option becomes exercisable in four equal installments commencing 04/01/2017.
F12 Option becomes exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
F13 Option becomes exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised.
F14 Option becomes exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
F15 Option becomes exercisable in three equal installments commencing 04/01/2022.
F16 Option vests in three equal installments, on 8/31/2021, 8/31/2022 and 8/31/2023.
F17 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F18 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.